glp 1 agonists vs sglt2 inhibitors and GLP-1 Receptor in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Perioperative GLP-1/GIP & SGLT2 Inhibitors
Description
The primary outcome measure is time to first major adverse cardiovascular event
After some months of deliberation Knudsen decided the best way forward was to find something that could protect the GLP-1 molecule
Your genetic makeup, metabolic biomarkers, lifestyle factors, and access considerations all play a role
The deeper reality is that GLP-1 medications reshape your microbiome, and the state of your microbiome determines how you experience those digestive changes
W.GreigN
